Compare SCCO & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCCO | VRTX |
|---|---|---|
| Founded | 1952 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | EDP Services |
| Sector | Basic Materials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.3B | 115.7B |
| IPO Year | N/A | 1991 |
| Metric | SCCO | VRTX |
|---|---|---|
| Price | $188.05 | $478.59 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 10 | 27 |
| Target Price | $124.28 | ★ $509.17 |
| AVG Volume (30 Days) | ★ 1.9M | 1.3M |
| Earning Date | 02-11-2026 | 02-12-2026 |
| Dividend Yield | ★ 1.94% | N/A |
| EPS Growth | ★ 25.54 | N/A |
| EPS | 4.67 | ★ 14.22 |
| Revenue | ★ $12,334,600,000.00 | $11,723,300,000.00 |
| Revenue This Year | $15.74 | $10.93 |
| Revenue Next Year | $6.81 | $8.44 |
| P/E Ratio | $39.43 | ★ $32.93 |
| Revenue Growth | ★ 12.70 | 10.33 |
| 52 Week Low | $72.75 | $362.50 |
| 52 Week High | $191.22 | $519.68 |
| Indicator | SCCO | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 71.64 | 62.38 |
| Support Level | $174.45 | $429.00 |
| Resistance Level | $191.22 | $472.58 |
| Average True Range (ATR) | 6.86 | 13.74 |
| MACD | 1.03 | 1.07 |
| Stochastic Oscillator | 88.22 | 82.72 |
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. It generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. The company's geographical segments are The Americas, Europe, and Asia.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.